Mina Sooch - 06 Sep 2022 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Role: President and CEO, Director
Signature: /s/ Stephanie Swan, by Power of Attorney
Issuer symbol: IRD
Transactions as of: 06 Sep 2022
Net transactions value: +$0.1023
Form type: 4
Filing time: 08 Sep 2022, 16:01:37 UTC
Previous filing: 23 May 2022
Next filing: 14 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUP	Common Stock	Exercise of in-the-money or at-the-money derivative security	$0.1023	+1,023	+0.24%	$0.000100^*	426,045	06 Sep 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCUP	Series B Warrant (right to buy)	Exercise of in-the-money or at-the-money derivative security	$0	-1,023	-100%	$0.000000^*	0	06 Sep 2022	Common Stock	1,023	$0.000100	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The expiration date of the Series B Warrants occurred on the later of (x) the Reservation Date (as defined in the Series B Warrants) and (y) the date on which the Series B Warrant has been exercised in full.